Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Rises By 161.6%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 29,166,975 shares, a growth of 161.6% from the December 31st total of 11,149,487 shares. Approximately 1,462.7% of the company’s shares are sold short. Based on an average daily trading volume, of 84,020,039 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily trading volume, of 84,020,039 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1,462.7% of the company’s shares are sold short.

Institutional Trading of Aspire Biopharma

A number of institutional investors have recently bought and sold shares of the company. Optivise Advisory Services LLC grew its holdings in shares of Aspire Biopharma by 120.9% during the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after buying an additional 128,660 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after buying an additional 131,533 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Aspire Biopharma during the 3rd quarter valued at $28,000. Finally, Crewe Advisors LLC lifted its stake in shares of Aspire Biopharma by 100.0% in the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock worth $169,000 after acquiring an additional 313,427 shares in the last quarter. 19.17% of the stock is currently owned by hedge funds and other institutional investors.

Aspire Biopharma Price Performance

NASDAQ:ASBP opened at $1.59 on Thursday. The firm has a market cap of $4.28 million, a price-to-earnings ratio of -0.08 and a beta of 0.81. The firm’s fifty day moving average price is $3.65 and its 200 day moving average price is $11.15. Aspire Biopharma has a 1-year low of $1.42 and a 1-year high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($1.60) EPS for the quarter. The business had revenue of $0.00 million for the quarter.

Analysts Set New Price Targets

A number of research firms have issued reports on ASBP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Wednesday, January 21st. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aspire Biopharma currently has a consensus rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.